However, concomitant combination with PD-1 blockade is essential, otherwise even increased tumor-infiltrating T cells will be invalidated by the suppression of PD-1/PD-L1 pathway, which has been confirmed by in vivo antitumor studies. This evidence concerns the gene CD274 and neoplasm.